New data in breast and ovarian cancer presented at ASCO support continued development of Iniparib
Posted: 6 June 2011 | | No comments yet
Sanofi announced new data for iniparib (BSI-201)…
Sanofi (EURONEXT: SAN and NYSE: SNY) today announced new data for iniparib (BSI-201), an investigational agent, in metastatic triple-negative breast cancer (mTNBC), platinum-sensitive and platinum-resistant recurrent ovarian cancer. The data were presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Metastatic Triple-negative Breast Cancer
Results from the randomized, open-label, Phase III trial investigating the use of gemcitabine and carboplatin with or without iniparib in mTNBC were presented by Joyce O’Shaughnessy, MD, lead investigator of the study and co-chair of the Breast Cancer Research Program, Baylor-Charles A. Sammons Cancer Center, Texas Oncology, US Oncology in Dallas. The results showed that:
- The study did not reach statistical significance for the co-primary endpoints of Overall Survival (HR=0.88, 95% CI [0.69, 1.12]; p=0.28 [versus pre-specified at 0.04]) or Progression-free Survival (HR=0.79, 95% CI [0.65, 0.98]; p=0.027 [versus pre-specified at 0.01]).
- In a preplanned sub-group analysis of patients in the second- and third-line treatment settings, the median Progression-free Survival was 4.2 months in the iniparib arm, compared to 2.9 months in the chemotherapy alone arm (HR=0.67, 95% CI [0.5, 0.92]). The median Overall Survival was 10.8 months in the iniparib arm, compared to 8.1 months in the chemotherapy alone arm (HR=0.65, 95% CI [0.46, 0.91]).
- The most common adverse events (Grade 3/4, >5%) in the iniparib arm were neutropenia, thrombocytopenia, anemia, fatigue, increase in alanine aminotransferase and dyspnea. The addition of iniparib did not significantly add to the toxicity profile of gemcitabine and carboplatin.
“Patients with metastatic triple-negative breast cancer have very few treatment options available to them,” said Dr. O’Shaughnessy. “I am encouraged by the second- and third-line data from this trial and believe further investigation is warranted in an effort to alleviate this unmet medical need.”
Platinum-sensitive Recurrent Ovarian Cancer
Data from a preliminary analysis of an ongoing multi-center, single-arm Phase II trial evaluating gemcitabine and carboplatin in combination with iniparib in platinum-sensitive recurrent ovarian cancer presented by Richard T. Penson, MD, Clinical Director, Medical Gynecologic Oncology, Massachusetts General Hospital in Boston demonstrated that:
- The Overall Response Rate (complete plus partial responses) was 65% in 40 evaluable patients.
- The most common adverse events (Grade 3/4, >5%) were: neutropenia, thrombocytopenia, diarrhea, and anemia.
Platinum-resistant Recurrent Ovarian Cancer
Results from a preliminary analysis of a multi-center, single-arm Phase II trial evaluating gemcitabine and carboplatin in combination with iniparib in platinum-resistant recurrent ovarian cancer presented by Michael Birrer, MD, PhD, Director, Medical Gynecologic Oncology, Massachusetts General Hospital in Boston demonstrated that:
- The Overall Response Rate (complete plus partial responses) was 25% in 32 evaluable patients.
- The most common adverse events (Grade 3/4, >5%) were: neutropenia, thrombocytopenia, nausea, anemia, small intestinal obstruction, abdominal pain, and fatigue.
“These results again demonstrate that iniparib is an active agent and can be combined with standard chemotherapy,” said Debasish Roychowdhury, MD, Senior Vice President and Head of Sanofi Oncology. “Sanofi is committed to further developing iniparib based on activity seen to date with this molecule.”
About the Studies
The randomized, open-label Phase III mTNBC study enrolled 519 women from 109 sites in the US. Patients were randomized to receive a standard chemotherapy regimen (gemcitabine and carboplatin) on days one and eight of each 21-day cycle, with or without iniparib (BSI-201) 5.6 mg/kg, which was administered on days one, four, eight and 11 of each 21-day cycle. Patients in the study had received up to two previous lines of chemotherapy in a metastatic setting. The co-primary endpoints were Overall Survival or Progression-free Survival.
The multi-center single-arm Phase II recurrent ovarian cancer studies evaluated the same treatment regimen of gemcitabine/carboplatin with or without iniparib used in the mTNBC study. The platinumsensitive study included 41 patients whose disease recurred at least six months after completing treatment with a platinum-based chemotherapy agent, while the platinum-resistant study continues to enroll up to 48 patients whose disease recurred between two and six months following treatment with a platinum-based chemotherapy agent. The primary endpoint of both trials was Overall Response.
About Iniparib (BSI-201)
BSI-201 is a novel, investigational oncology agent that is in Phase III trials for patients with squamous non-small cell lung cancer (NSCLC), as well as in Phase II trials for patients with breast, lung and other cancers. In addition, BSI-201 is the subject of an extensive translational program designed to identify biomarkers predictive of response both within and across tumor types. Iniparib is the United States Adopted Name (USAN) for BSI-201.